Bryan F. Cox Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Bryan F. Cox sold 4,764 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $24,677.52. Following the transaction, the insider now owns 119,415 shares of the company’s stock, valued at $618,569.70. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

TriSalus Life Sciences Trading Down 1.7%

NASDAQ:TLSI opened at $5.35 on Friday. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $9.85. The company has a market cap of $172.66 million, a PE ratio of -2.15 and a beta of 0.50. The company has a 50 day simple moving average of $5.41 and a two-hundred day simple moving average of $5.03.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period in the previous year, the business posted ($0.60) earnings per share. Research analysts forecast that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences in the 1st quarter worth approximately $187,000. Charles Schwab Investment Management Inc. bought a new stake in TriSalus Life Sciences in the 1st quarter worth approximately $55,000. Connective Capital Management LLC bought a new stake in TriSalus Life Sciences in the 4th quarter worth approximately $140,000. Bridgeway Capital Management LLC grew its position in TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock worth $326,000 after purchasing an additional 50,000 shares during the period. Finally, Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after purchasing an additional 178,298 shares during the period. Institutional investors own 2.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TLSI shares. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They set a “buy” rating and a $10.00 target price for the company. Roth Mkm restated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $10.93.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.